Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 15/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.81 |
| ▸ | CYP1A2 | P05177 | 6/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.81 |
| ▸ | FYN | P06241 | 2/20 | 0.81 |
| ▸ | YES1 | P07947 | 2/20 | 0.81 |
| ▸ | SRC | P12931 | 2/20 | 0.81 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.81 |
| ▸ | RAB29 | O14966 | 1/20 | 0.81 |
| ▸ | LYN | P07948 | 1/20 | 0.81 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.81 |
| ▸ | KDR | P35968 | 1/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1623566 | 0.89 | AURKA (1.00) | AURKACYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1623685 | 0.88 | AURKA (0.83) | AURKACYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1623635 | 0.87 | AURKA (0.85) | AURKACYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1620935 | 0.86 | AURKA (0.84) | AURKACYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1623689 | 0.86 | AURKA (0.81) | AURKACYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1621534 | 0.86 | AURKA (0.81) | AURKACYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1623711 | 0.85 | AURKA (0.78) | AURKACYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1622913 | 0.85 | AURKA (0.78) | AURKACYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL12721002 | 0.84 | AURKA (0.58) | AURKACYP3A4CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1623763 | 0.83 | AURKA (0.80) | AURKACYP3A4CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1876178-B1 | CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-05-27 | — | — | EP | disclosed |
| EP-1876178-B1 | CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE | MITSUBISHI TANABE PHARMA CORP (JP) | 2015-05-27 | — | — | EP | disclosed |
| US-7928126-B2 | Cyanopyridine derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-04-19 | — | — | US | disclosed |
| US-20090292121-A1 | Cyanopyridine derivative and use thereof as medicine | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-11-26 | — | — | US | disclosed |
| EP-1876178-A1 | CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-01-09 | — | — | EP | disclosed |
| EP-1876178-A1 | CYANOPYRIDINE DERIVATIVE AND USE THEREOF AS MEDICINE | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090292121-A1 | Cyanopyridine derivative and use thereof as medicine | DPYD, IDH1, TP53 | AURKA 172/4885CYP3A4 177/4885CYP1A2 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.